Section
A Sept 22, 2026 Annals of Oncology editorial from Stanford and University of South Carolina authors urges retiring 'negative' oncology names such as triple-negative breast cancer and non-small cell lung cancer in favour of molecularly defined entities, proposing hybrid transitional labels and biology-driven pathology reporting.
In women aged 65 and older with cT2N0 hormone receptor-positive, HER2-negative breast cancer, sentinel lymph node biopsy rarely alters adjuvant therapy plans, supporting a more individualized approach to axillary staging in this population.
This study highlights the prevalence, clinical features, and management challenges of immune-related thyroid and diabetes toxicities in gynecologic cancer patients treated with immunotherapy, emphasizing the need for proactive endocrine mon
This study reveals that lower serum GLP-1 levels are independently associated with endometrial cancer in obese, non-diabetic women, suggesting its potential as a diagnostic biomarker with high sensitivity and specificity.
A retrospective series evaluating high-dose oral vitamin D demonstrated rapid improvement and symptom relief in patients with chemotherapy- and radiation-induced skin toxicity without adverse effects, supporting its potential role in oncode
This study assesses early postoperative complications following tissue expander breast reconstruction using polydioxanone synthetic mesh, biologic mesh, or no mesh, revealing comparable short-term outcomes and highlighting factors like radi
Delaying acellular dermal matrix (ADM) placement to the second-stage implant exchange in prepectoral 2-stage breast reconstruction reduces capsular contracture rates without increasing tissue expander loss, although seroma risk may rise in
A pooled analysis of REPRIME-FIL and CART-SIE studies shows CAR T-cell therapy significantly improves overall survival in relapsed/refractory primary mediastinal B-cell lymphoma compared to traditional salvage treatments including ASCT.
BCMA-targeted CAR T-cell therapy demonstrates substantial efficacy and an acceptable safety profile as a salvage option for relapsed/refractory multiple myeloma patients after failure of prior anti-GPRC5D CAR T-cell treatments.
Hematologists and oncologists possess critical skills to address hematologic complications of acute radiation syndrome and are essential in bolstering mass casualty radiation response, utilizing existing resources and infrastructure for eff
Extended venous thromboembolism prophylaxis using once-daily subcutaneous enoxaparin post-pancreatectomy does not significantly reduce thrombotic events; higher BMI heightens risk, signaling a need for optimized, possibly weight-based dosin
This review evaluates whether sentinel lymph node biopsy omission, validated in SOUND and INSEMA trials, applies to cT1N0 invasive lobular carcinoma, highlighting nodal positivity rates, risk factors such as lymphovascular invasion, and cli
This study analyzes treatment patterns, outcomes, and prognostic factors in 344 patients with transformed follicular lymphoma in the rituximab era, revealing poor event-free survival but moderate overall survival and high relapse rates, gui
This article explores the discovery of NSD2-ligand-directed degrader (NSD2-LDD), a promising targeted therapy that degrades oncogenic NSD2 in t(4;14) multiple myeloma, reversing malignant epigenomic programs and improving disease outcomes i
This study evaluates the safety and clinical outcomes of immune checkpoint inhibitor rechallenge in classical Hodgkin lymphoma patients following immune-related adverse events, demonstrating feasibility and preserved efficacy in selected ca
A multidisciplinary consensus provides practical, trial-design focused recommendations for testing systemic therapies around surgery or combined with locoregional treatment in hepatocellular carcinoma, emphasizing patient selection, endpoin
This review analyzes global sex disparities in cancer incidence, highlighting modifiable lifestyle and health factors — notably smoking, alcohol, and obesity — as key contributors differing by population context, with implications for tailo
Recent advances in identifying leukemia-restricted antigens enable subtype-specific immunotherapies in AML that selectively target malignant cells while sparing normal hematopoiesis, offering a promising new paradigm for precision treatment
This article examines how the timing of bilateral salpingo-oophorectomy (BSO) affects the lifetime ovarian cancer risk in women carrying BRCA1 or BRCA2 mutations, emphasizing the benefits of preventive surgery and its residual risk reductio
This phase II study evaluates pembrolizumab combined with carboplatin/paclitaxel and HIPEC in neoadjuvant therapy, followed by pembrolizumab maintenance with or without olaparib in advanced stage III/IV epithelial ovarian cancer patients.
